



9113184

1FW

Docket 17322CON2CIP1 (AP)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:
DREYER, et al.

Serial No.: 10/734,930

Filed: December 12, 2003

For: CALCIUM BLOCKERS TO TREAT
PROLIFERATIVE RETINAL DISEASES

Examiner: Zohreh A. Fay (parent app.)

Group Art Unit: 1614

Confirmation No. 2241

Irvine, California

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop: Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Applicants provide with regard to the above-identified patent application entitled CALCIUM BLOCKERS TO TREAT PROLIFERATIVE RETINAL DISEASES, one copy of documents of which they are aware, which may be material to the examination of this application, and in respect of which there may be a duty of disclosure under 37 C.F.R. §1.56. A listing of the documents submitted is set forth on the attached 2 page Information Disclosure Citation (Form PTO-1449).

While these documents may be material pursuant to 37 C.F.R. §1.56, the disclosure is not intended to constitute an admission that the documents are prior art in regard to this invention. The filing of this Statement should not be construed to mean that a search has been conducted or that no other material

documents or information exists. Please do not hesitate to contact the undersigned should any questions arise regarding this Statement.

The Commissioner is hereby authorized to charge any fees required or necessary for the filing, processing or entering of this paper or any of the enclosed papers, and to refund any overpayment, to deposit account 01-0885.

Respectfully submitted,

Date: September 10, 2004



Brent A. Johnson
Patent Agent
Registration Number 51,851

Please direct all inquiries and correspondence to:

Brent A. Johnson
Allergan, Inc.
2525 Dupont Drive, T2-7H
Irvine, California 92623-9534
Tel: (714) 246-4348
Fax: (714) 246-4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Information Disclosure Statement and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date September 10, 2004 in an envelope as "Express Mail Post Office to Addressee" Mailing Label number EV193720291US addressed to Mail Stop: Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Susan Bartholomew

Name of person mailing paper



Signature of person signing paper

Date September 10, 2004



LIST OF ART CITED BY APPLICANT

ATTY. DOCKET NO.: 13322CON&CIP1 (AP)	SERIAL NO.: 10/734,930
APPLICANTS: DREYER, et al.	TITLE: CALCIUM BLOCKERS TO TREAT PROLIFERATIVE RETINAL DISEASE
FILING DATE: DECEMBER 12, 2003	GROUP: 1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUB-CLASS	FILING DATE (if applicable)
	AA	5,521,215	5-28-96	Mechoulam, et al.			
	AB						
	AC						
	AD						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (yes/no)
	BA	WO 90/06118	14.06.1990	PCT			
	BB	WO 97/01339	16.01.1997	PCT			
	BC	WO 99/25350	27.05.1999	PCT			
	BD	FR 2 738 568 A1	08.09.1995	France			No

OTHER ART

(Including Author, Title, Date, Pertinent Pages, etc.)

	CA	Kapin, M.A., et al., "Protective effects of the polyamine antagonist, eliprodil hydrochloride in retina subjected to an society for neuroscience" <i>Society for Neuroscience Abstracts</i> , Vol. 22, No. 1-03 16. Nov 1996, pg. 1279
	CB	
	CC	
	CD	
	CE	
	CF	
	CG	
	CH	
	CI	
	CJ	
	CK	
	CL	
	CM	
	CN	

EXAMINER _____ DATE CONSIDERED _____

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.